AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Plasminogen

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P00747

UPID:

PLMN_HUMAN

Alternative names:

-

Alternative UPACC:

P00747; Q15146; Q5TEH4; Q6PA00

Background:

Plasminogen, a critical protein, plays a pivotal role in fibrinolysis, the process of breaking down fibrin blood clots. Beyond its well-known function in clot dissolution, plasminogen is instrumental in various physiological processes including tissue remodeling, embryonic development, and the modulation of inflammation. Its ability to activate several proteolytic factors and cleave components like fibronectin and laminin underscores its importance in cellular functions.

Therapeutic significance:

Plasminogen deficiency, manifesting in two forms, underscores the protein's clinical relevance. Type 1 deficiency leads to severe fibrinolysis impairment and chronic mucosal lesions, with ligneous conjunctivitis being a hallmark symptom. Additionally, plasminogen's role in hereditary angioedema highlights its potential as a therapeutic target. Understanding the multifaceted functions of plasminogen could pave the way for innovative treatments for these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.